Cancer and renal insufficiency results of the BIRMA study
(2010) The British journal of cancer — Vol. 103, n° 12, p. 1815-1821 (2010)
Files
6605979a.pdf
Open Access - Adobe PDF
- 292.61 KB
Details
- Authors
- Abstract
- Background: half of anticancer drugs are predominantly excreted in urine. Dosage adjustment in renal insufficiency (RI) is, therefore, a crucial issue. Moreover, patients with abnormal renal function are at high risk for drug-induced nephrotoxicity. The Belgian Renal Insufficiency and Anticancer Medications (BIRMA) study investigated the prevalence of RI in cancer patients, and the profile/dosing of anticancer drugs prescribed. Methods: primary end point: to estimate the prevalence of abnormal glomerular filtration rate (GFR; estimated with the abbreviated Modification of Diet in Renal Disease formula) and RI in cancer patient. Secondary end point: to describe the profile of anticancer drugs prescribed (dose reduction/nephrotoxicity). Data were collected for patients presenting at one of the seven Belgian BIRMA centres in March 2006. Results: a total of 1218 patients were included. The prevalence of elevated SCR (> or =1.2 mg per 100 ml) was 14.9%, but 64.0% had a GFR<90 ml min(-1) per 1.73 m(2). In all, 78.6% of treated patients (n=1087) were receiving at least one drug needing dosage adjustment and 78.1% received at least one nephrotoxic drug. In all, 56.5% of RI patients receiving chemotherapy requiring dose reduction in case of RI did not receive dose adjustment. Conclusions: the RI is highly frequent in cancer patients. In all, 80% of the patients receive potentially nephrotoxic drugs and/or for which dosage must be adjusted in RI. Oncologists should check the appropriate dose of chemotherapeutic drugs in relation to renal function before prescribing.
- Affiliations
Citations
Janus, N., Launay-vacher, V., Byloos, E., Machiels, J.-P., Duck, L., Kerger, J., Wynendaele, W., Canon, J.-L., Lybaert, W., Nortier, J., Deray, G., & Wildiers, H. (2010). Cancer and renal insufficiency results of the BIRMA study. The British journal of cancer, 103(12), 1815-1821. https://doi.org/10.1038/sj.bjc.6605979 (Original work published 2010)